----------------------------------------
QUESTION 12:
After publication, should access include the deposit of
biological materials as set forth in 37 CFR 1.802 et seq.?
----------------------------------------
FROM RESPONDENT 001:
NAME: David E. Craword, Jr. (Reg No. 38,118)
COMPANY: ROGERS, HOWELL & HAFERKAMP
COUNSELLORS AT LAW
ADDR-1: PIERRE LACLEDE CENTER, SUITE 1400
7733 F0RSYTH BOULEVARD
CITY, STATE ZIP: ST.LOUIS, MISS0URI 63105-1817
TELEPHONE: (314) 727-5188
FAX:
REPRESENT: unclear
----------------------------------------
COMMENT ON QUESTION 12:
-------
001-Q12.TXT
Yes. A less than enabling disclosure defeats the goals of publishing
the application in the first place. Omission of a biological material
deposit causes a less than enabling disclosure.
----------------------------------------
FROM RESPONDENT 026:
NAME: Louis Maassel
COMPANY: World Intellectual Property Organization, Geneva, Switzerland
ADDR-1: 12716 Buckingham Drive
CITY, STATE ZIP: Bowie, Maryland 20715
TELEPHONE: 301) 464-4306
FAX:
REPRESENT: self
----------------------------------------
COMMENT ON QUESTION 12:
No comment.
----------------------------------------
FROM RESPONDENT 041:
NAME: Frederick S. Burkhart
COMPANY: INTELLECTUAL PROPERTY LAW SECTION
OF THE. STATE. BAR OF MICHIGAN
ADDR-1: 306 TOWNSEND STREET
CITY, STATE ZIP: LANSING, MICHIGAN 48933
TELEPHONE: 517-372-9030
FAX:
REPRESENT: association
----------------------------------------
COMMENT ON QUESTION 12:
It is the understanding of this Committee that other countries which publish patent applications at 18 months allow access to the deposit of biological materials upon publication. In order to promot e harmonization, the United States Patent and Trademark Office should adopt a compatible practice.
----------------------------------------
FROM RESPONDENT 019:
NAME: Wilmot H. McCutchen, President
COMPANY: HOUSTON INVENTORS ASSOCIATION
ADDR-1:
CITY, STATE ZIP: HOUSTON, TEXAS
TELEPHONE: (713) 957 4344
FAX: (713) 868-4104
REPRESENT: COMPANY
----------------------------------------
COMMENT ON QUESTION 12:
-------
019-Q12.TXT
Biological materials should not be made accessible to the public
after publication without the express consent of the applicant, for
the- reasons stated in response to Question 10 Our law forbids file
access without consent 3S USC 122 Appendix "D"]
----------------------------------------
FROM RESPONDENT 010:
NAME: Scott Weide
COMPANY: QUIRK & TRATOS
ADDR-1: 550 E. CHARLESTON BLVD. . SUITE D
CITY, STATE ZIP: LAS VEGAS NEVADA 89104
TELEPHONE: (702) 386-1778
FAX:
REPRESENT: firm
----------------------------------------
COMMENT ON QUESTION 12:
-------
010-Q12.TXT
No. Such would be overly burdensome of the Patent Office and perhaps,
the applicant.
----------------------------------------
FROM RESPONDENT 029:
NAME: Marcia H. Sundeen
COMPANY: PENNIE & EDMONDS
ADDR-1: 1701 Pennsylvania Avenue, N.W.
CITY, STATE ZIP: Washington, D.C. 20006-4706
TELEPHONE: (202) 393-0177
FAX: (202) 393 0462
REPRESENT: PTO Relations Committee
----------------------------------------
COMMENT ON QUESTION 12:
-------
029-Q12.TXT
Yes.
----------------------------------------
FROM RESPONDENT 033:
NAME: TOM EASTEP
COMPANY: THE ALLIANCE FOR AMERICAN INNOVATION
ADDR-1: 1100 Connecticut Ave. NW, Suite 1200
CITY, STATE ZIP: Washington, D.C 20036-4101
TELEPHONE: 202-293-1414
FAX: 202-467-5591
REPRESENT: ALLIANCE FOR AMERICAN INNOVATION
----------------------------------------
COMMENT ON QUESTION 12:
-------
033-Q12.TXT
YES.
----------------------------------------
FROM RESPONDENT 008:
NAME: Gabriel P. Katona
COMPANY: Schweitzer Cornman & Gross
Attorneys at Law
ADDR-1: 230 Park Avenue
CITY, STATE ZIP: New York, New York 10169-0059
TELEPHONE: (212) 986-3377
FAX: (212) 986-6126
REPRESENT: unclear
----------------------------------------
COMMENT ON QUESTION 12:
-------
008-Q12.TXT
Since the biological deposit is a part of the disclosure, it should
be accessible on the basis of the depository information in the
bibliographic details of the database I am not convinced that the
depository information should be included in the OG publication or
only in the application information in the database, because
inclusion in the publication may represent further difficulties and
possible delays in publication
----------------------------------------
FROM RESPONDENT 004:
NAME: Michael H. Minns
COMPANY: INGERSOLL-RAND COMPANY
Patent Department
ADDR-1: 942 Memorial Parkway
CITY, STATE ZIP: Phillipsburg, NJ 08865
TELEPHONE: (908)859-7700
FAX: (908) 859-7707
REPRESENT: self
----------------------------------------
COMMENT ON QUESTION 12:
-------
004-Q12.TXT
No comment.
----------------------------------------
FROM RESPONDENT 025:
NAME: Yukiji Kobayashi, President
COMPANY: Japan Intellectual Property Association
ADDR-1: Shintomi 1-chome Bld;. 7F
9 8, Shintomi 1~chome
CITY, STATE ZIP: Chuo~ku. TokYo 104, JAPAN
TELEPHONE: 813 3206 2243
FAX: 81 3 3206 2230
REPRESENT: association
----------------------------------------
COMMENT ON QUESTION 12:
-------
025-Q12.TXT
From the view point of publication of invention, it is theoretically
conceivable that the biological material is open to furnishing as
well at the time of publication of specification, but due to the
special nature of biological material patent laws in Europe and in
Japan limits furnishing at the time of publication of invention. It
is desired that USPTO would do the same. (Response to your question
#12)
Last Modified: March 1995